D‐Ribose Induced NLRP3 Inflammasome Activation in Podocytes by Increase in Advanced Glycation End‐Products
Jinni Hong,Qinghua Zhang,Guangbi Li,Joseph Ritter,Weiwei Li,Xuemei Wang,Pinlan Li
DOI: https://doi.org/10.1096/fasebj.2018.32.1_supplement.832.17
2018-01-01
Abstract:Recent studies have demonstrated that D‐ribose levels are increased in patients with type II diabetes mellitus and that increased blood D‐ribose levels are involved in the development of diabetic complications such as diabetic encephalopathy and nephropathy. However, the mechanisms mediating the pathogenic role of D‐ribose remain poorly understood. In the present study, we treated podocytes with different concentrations of D‐ribose and examined its potential effects on NLRP3 inflammasome activation and podocyte function. Using confocal microscopy, D‐ribose was found to markedly increase the co‐localization of caspase‐1 and NLRP3 by 1.8 folds compared to control, which suggests enhanced NLRP3 inflammasome formation. By ELISA, we demonstrated that in podocytes treated with D‐ribose, a major product of NLRP3 inflammasome‐IL‐1β was significantly increased by 2.05 folds, indicating the activation of NLRP3 inflammasomes. Western blot analysis further confirmed that D‐ribose increased the level of active caspase‐1 in podocytes by 2.09 folds, another parameter for activation of NLRP3 inflammasomes, which was substantially attenuated by caspase‐1 inhibitor, YvAD and ROS scavenger, NAC, respectively. In addition, D‐ribose‐induced NLRP3 inflammasome activation could be blocked by inhibitor of advanced glycation end‐products (AGEs) formation and their chemical breaker or receptor antagonist, aminoguanidine, aylthiazolium chloride and RAGE siRAGE by 43%, 50% and 73%, respectively. These results suggest that D‐ribose induces NLRP3 inflammasome activation in podocytes in an AGE‐dependent manner, which may be a triggering mechanism of diabetic nephropathy.Support or Funding InformationSupported by NIH grants DK54927 and HL075316 to Pinlan Li, NSFC grants 81573763 to Weiwei Li, and NSFC grants 81530099 to Xuemei WangThis abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.